First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)

NCT ID: NCT04203576

Last Updated: 2025-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-22

Study Completion Date

2029-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

First in Human Clinical Investigation of the FIRE1 Device/System to evaluate the feasibility and safety of implanting the FIRE1 system in up to 50 stable HF patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients who have HF and were hospitalised/treated for an episode of worsening HF within the last 6 months. This non-randomised FIH trial will enrol a total of 50 patients and the primary safety and technical endpoints will be assessed at 3 months. Safety measures will include an assessment of all adverse events. Subjects will remain in this study for 24 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FIRE1 System

FIRE1 System

Group Type EXPERIMENTAL

FIRE1 System

Intervention Type DEVICE

FIRE1 System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FIRE1 System

FIRE1 System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults 18 years or older with heart failure with any of the following in the past 6 months: a decompensation due to heart failure resulting in a heart failure hospitalisation, heart failure treatment in a hospital day-care setting or urgent outpatient heart failure visit
* Receiving treatment in accordance with internationally recognised guidelines.
* Signed patient informed consent form

Exclusion Criteria

* Significant comorbidity that would interfere with the ability to safely complete the clinical investigation protocol
* Patients with an estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min
* Patients with IVC filter placement in situ, abnormal IVC or femoral venous anatomy or known congenital malformation or absence of IVC or occlusive or free-floating thrombus in the IVC
* Patients with implantable ventricular assist device (LVAD, RVAD, BiVAD) in situ
* Patients with Cardiovascular Implantable Electronic Device (CIED) implanted ≤ 3 months prior to enrolment
* Patients with conditions associated with occlusion of the IVC, iliac or common femoral veins (e.g. venous leg ulcers)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Foundry Innovation & Research 1, Limited (FIRE1)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Annette Kent

Role: STUDY_DIRECTOR

Clinical Director

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nemocnice Na Homolce

Prague, Praha 5, Czechia

Site Status

Fakultní Nemocnice Brno

Brno, , Czechia

Site Status

Israeli-Georgian Medical Research Clinic Helsikor

Tbilisi, , Georgia

Site Status

Tbilisi Heart and Vascular Clinic

Tbilisi, , Georgia

Site Status

Galway University Hospital

Galway, , Ireland

Site Status

Erasmus University Medical Center

Rotterdam, Dr. Molewaterplein 40, Netherlands

Site Status

University Medical Center, Groningen

Groningen, Hanzeplein 1, Netherlands

Site Status

Royal Bournemouth Hospital

Bournemouth, , United Kingdom

Site Status

Golden Jubilee National Hospital

Glasgow, , United Kingdom

Site Status

Glenfield Hospital

Leicester, , United Kingdom

Site Status

Royal Brompton Hospital Sydney Street

London, , United Kingdom

Site Status

Queen Alexandra Hospital

Portsmouth, , United Kingdom

Site Status

University Hospital Southampton

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Czechia Georgia Ireland Netherlands United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Kalra PR, Gogorishvili I, Khabeishvili G, Malek F, Toman O, Critoph C, Flett AS, Cowburn PJ, Mehra MR, Sheridan WS, Britton JR, Buxo T, Kealy RM, Kent A, Greene BR, Guha K, Gardner RS, Loke I, Vazir A, Brugts JJ, Gray A, Testani JM, Damman K. First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure: FUTURE-HF. JACC Heart Fail. 2025 Jun;13(6):1000-1010. doi: 10.1016/j.jchf.2025.01.019. Epub 2025 Apr 9.

Reference Type DERIVED
PMID: 40208140 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TF01-CID04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Heart Failure Patients Registry
NCT04709263 COMPLETED